Research Keyword: fungal burden

Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model

Researchers tested a new antifungal medication called rezafungin to treat a serious eye infection caused by the fungus Candida albicans. Using rabbit models, they found that rezafungin was much more effective than two other antifungal drugs at clearing the infection from the eye and preventing damage to vision. The drug’s ability to work for longer periods with less frequent dosing makes it a promising candidate for treating this devastating infection in patients.

Read More »

Mycobiome analyses of critically ill COVID-19 patients

This study examined fungal infections in severely ill COVID-19 patients treated in intensive care units across Europe. Researchers found that a dangerous mold called Aspergillus fumigatus was more common in patients who died and less common in those treated with azole antifungal drugs. The findings suggest that giving antifungal medications to critically ill COVID-19 patients when they arrive at the hospital might help prevent fungal-related deaths.

Read More »

Fluconazole worsened lung inflammation, partly through lung microbiome dysbiosis in mice with ovalbumin-induced asthma

Fluconazole is an antifungal medication that works well for treating asthma caused by fungal infections, but may actually worsen asthma from other causes. In mice with allergic asthma, fluconazole killed beneficial bacteria and promoted the growth of harmful bacteria that increased inflammation. This study suggests that fluconazole should only be used for fungal-related asthma and careful monitoring is needed if used in patients with regular asthma.

Read More »

Efficacy of SCY-247, a Second-generation Triterpenoid Antifungal, in Three Murine Models of Invasive Fungal Infections

Researchers tested a new antifungal drug called SCY-247 in mice to treat serious fungal infections. The drug was given orally and showed strong effectiveness against common fungal infections caused by Candida and Rhizopus species, including strains resistant to current treatments. Higher doses of the drug produced better results, and the drug effectively concentrated in the organs most affected by fungal infections.

Read More »
Scroll to Top